Future trends and issues in erythropoietin. Part II.
Although recombinant human erythropoietin (rHuEPO) has only been approved for clinical use since 1989, its beneficial effects in the treatment of anemia in patients with chronic renal failure has been clearly demonstrated. Bolstered by this success, clinical investigators are now turning to other types of anemia that might benefit from such therapy. Part II of this article will continue to discuss some of the potential areas of clinical application for rHuEPO. Part I was published last month in NN&I.
Stevenson
K D
KD
D000740:Anemia / Q000188:drug therapy; D000755:Anemia, Sickle Cell / Q000188:drug therapy; D004921:Erythropoietin / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008599:Menstruation Disturbances / Q000188:drug therapy; D010807:Physical Endurance / Q000187:drug effects; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin